Clinical Trial Update: A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of Opzelura (ruxolitinib) cream in adults with moderate atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Opzelura (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED